Harmine Suppresses Breast Cancer Cell Migration and Invasion by Regulating TAZ-mediated Epithelial-mesenchymal Transition

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2022 Jul 11

PMID 35812064

Authors

Jinrong He

Shanshan Chen

Tong Yu

Weiqun Chen

Jin Huang

Caixia Peng

Yu Ding

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a highly lethal disease due to cancer metastasis. Harmine (HM), a β-carboline alkaloid, is present in various medicinal plants. Our previous study demonstrated that HM suppresses cell proliferation and migration by regulating TAZ in breast cancer cells and accelerates apoptosis. Epithelial-mesenchymal transition (EMT) plays an important role in the development of breast cancer by inducing the characteristics of cancer stem cells, cancer metastasis and recurrence. Overexpression of TAZ was shown to mediate EMT in breast cancer cells. We aimed to investigate whether HM inhibits EMT and metastasis of breast cancer cells by targeting TAZ. In this study, the cells treated with HM or with downregulated expression of TAZ showed an increase in epithelial markers and decrease in mesenchymal markers in breast cancer cells. Consistently, the breast cancer cells treated with HM or with downregulated expression of TAZ showed suppressed migration and proliferation. Moreover, TAZ overexpression reversed EMT and metastasis induced by HM in breast cancer cells. Thus, HM suppresses EMT and metastasis and invasion by targeting TAZ in breast cancer cells. HM can be used as an anticancer drug for breast cancer treatment and chemoprevention.

Citing Articles

Role, mechanisms and effects of in anti‑breast cancer (Review).

Jiang S, Li C, Liu D, Zeng F, Wei W, He T Oncol Lett. 2025; 29(4):166.

PMID: 39963320 PMC: 11831725. DOI: 10.3892/ol.2025.14912.

Anti-tumor potential of Harmine and its derivatives: recent trends and advancements.

Joshi H, Bhushan S, Dimri T, Sharma D, Sak K, Chauhan A Discov Oncol. 2025; 16(1):189.

PMID: 39954215 PMC: 11829886. DOI: 10.1007/s12672-025-01893-w.

Role of Harmaline in Inhibiting c-Myc, Altering Molecular Typing, and Promoting Apoptosis in Triple-Negative Breast Cancer.

Xu H, Ma Y, Li H, Song X, Liu Y, Mierzhakenmu Z Breast Cancer (Dove Med Press). 2024; 16:855-866.

PMID: 39655230 PMC: 11626956. DOI: 10.2147/BCTT.S487070.

Research progress on the antitumor effects of harmine.

Hu Y, Yu X, Yang L, Xue G, Wei Q, Han Z Front Oncol. 2024; 14:1382142.

PMID: 38590646 PMC: 10999596. DOI: 10.3389/fonc.2024.1382142.

Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.

Bordeaux Z, Reddy S, Choi J, Braun G, McKeel J, Lu W Sci Rep. 2024; 14(1):1955.

PMID: 38263212 PMC: 10805783. DOI: 10.1038/s41598-024-52544-z.

References

Ge L, Li D, Chen F, Feng J, Li B, Wang T . TAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cells. Int J Oncol. 2017; 51(1):307-315. DOI: 10.3892/ijo.2017.3998. View

Zhang Y, Weinberg R . Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018; 12(4):361-373. PMC: 6186394. DOI: 10.1007/s11684-018-0656-6. View

Uhl K, Schultz C, Geerts D, Bachmann A . Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma. Cancer Cell Int. 2018; 18:82. PMC: 5992763. DOI: 10.1186/s12935-018-0574-3. View

Kaimori A, Potter J, Kaimori J, Wang C, Mezey E, Koteish A . Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem. 2007; 282(30):22089-101. DOI: 10.1074/jbc.M700998200. View

Ye X, Brabletz T, Kang Y, Longmore G, Nieto M, Stanger B . Upholding a role for EMT in breast cancer metastasis. Nature. 2017; 547(7661):E1-E3. PMC: 6283276. DOI: 10.1038/nature22816. View

Rokavec M, Oner M, Li H, Jackstadt R, Jiang L, Lodygin D . IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014; 124(4):1853-67. PMC: 3973098. DOI: 10.1172/JCI73531. View

Ruan S, Jia F, Li J . Potential Antitumor Effect of Harmine in the Treatment of Thyroid Cancer. Evid Based Complement Alternat Med. 2017; 2017:9402615. PMC: 5320370. DOI: 10.1155/2017/9402615. View

Bhat K, Salazar K, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F . The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011; 25(24):2594-609. PMC: 3248681. DOI: 10.1101/gad.176800.111. View

Ding Y, He J, Huang J, Yu T, Shi X, Zhang T . Harmine induces anticancer activity in breast cancer cells via targeting TAZ. Int J Oncol. 2019; 54(6):1995-2004. PMC: 6521938. DOI: 10.3892/ijo.2019.4777. View

10.

Tomaskovic-Crook E, Thompson E, Thiery J . Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009; 11(6):213. PMC: 2815537. DOI: 10.1186/bcr2416. View

11.

Yuan L, Zhou M, Wasan H, Zhang K, Li Z, Guo K . Jiedu Sangen Decoction Inhibits the Invasion and Metastasis of Colorectal Cancer Cells by Regulating EMT through the Hippo Signaling Pathway. Evid Based Complement Alternat Med. 2019; 2019:1431726. PMC: 6614995. DOI: 10.1155/2019/1431726. View

12.

Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C . The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147(4):759-72. DOI: 10.1016/j.cell.2011.09.048. View

13.

Chaffer C, San Juan B, Lim E, Weinberg R . EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016; 35(4):645-654. DOI: 10.1007/s10555-016-9648-7. View

14.

Yu S, Jing L, Yin X, Wang M, Chen Y, Guo Y . MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 2017; 8(59):99757-99771. PMC: 5725129. DOI: 10.18632/oncotarget.20909. View

15.

Matteucci E, Maroni P, Luzzati A, Perrucchini G, Bendinelli P, Desiderio M . Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. Eur J Cancer. 2012; 49(1):231-44. DOI: 10.1016/j.ejca.2012.05.006. View

16.

Benson J, Jatoi I . The global breast cancer burden. Future Oncol. 2012; 8(6):697-702. DOI: 10.2217/fon.12.61. View

17.

Pattabiraman D, Weinberg R . Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy. Cold Spring Harb Symp Quant Biol. 2017; 81:11-19. PMC: 5722631. DOI: 10.1101/sqb.2016.81.030957. View

18.

Geng X, Ren Y, Wang F, Tian D, Yao X, Zhang Y . Harmines inhibit cancer cell growth through coordinated activation of apoptosis and inhibition of autophagy. Biochem Biophys Res Commun. 2018; 498(1):99-104. PMC: 5857254. DOI: 10.1016/j.bbrc.2018.02.205. View

19.

Dobrokhotov O, Samsonov M, Sokabe M, Hirata H . Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms. Clin Transl Med. 2018; 7(1):23. PMC: 6087706. DOI: 10.1186/s40169-018-0202-9. View

20.

Du B, Shim J . Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016; 21(7). PMC: 6273543. DOI: 10.3390/molecules21070965. View